Introduction
Stents are intravascular implants used for the treatment of narrowed blood vessels. Bare metal stents often cause restenosis whereas drug-eluting stents minimize the neointimal growth and consequently reduce the incidence of restenosis [1] . To derive full benefit from the stent coating a sustained and controlled release rate of antiproliferative drug into the surrounding tissue is crucial. Commonly the drug release is controlled by a polymer layer in which the drug is incorporated. Therefore, coating integrity plays a decisive role in device performance. Nowadays stents are coated using coating techniques that have been especially developed for the purpose of stent coating. A substantial disadvantage of the commonly used coating methods are high costs which are partially due to the small output. The fluidized-bed process is an established method used in galenics for coating of large amounts of small dosage forms with high uniformity. The purpose of this research was to investigate the applicability of fluidized-bed process for coating of stents.
Methods
Bare-metal stents (117 pieces, ProKinetic 3.0 x 15 mm, Biotronik, Germany) and 250 steel springs of comparable measures used as filling material (length 14.6 mm, diameter 2.1 mm, Gutekunst &Co. KG, Germany) were coated in a bottom-spray fluidized-bed process using the MiniGlatt fluidized-bed apparatus equipped with the MicroKit product container, the Wurster bottom plate (Glatt GmbH, Germany) and a spray nozzle with an orifice diameter of 0.5 mm. The coating process was performed at 0.3 bar process pressure (quantity of inlet air 27 Nm³/h), 1.10 bar spray pressure, a spray rate of 4.4 g/min and an inlet air temperature of 80 °C that resulted in a target product temperature between 55-60 °C. The coating liquid consisted of the polymethacrylate Eudragit® RS30D (Röhm GmbH, Germany) dispersed in purified water. The almost water insoluble triamterene (Sigma Aldrich, Germany) served as a fluorescent model substance. To incorporate the poorly wettable triamterene the model substance was first dissolved in formic acid (99-100 %, Merck, Germany) and subsequently precipitated due to addition of purified water under continuous stirring. Afterwards the polymer was added. During the coating process the coating liquid was constantly stirred. The percentage composition (w/w) of coating liquid is shown in Tab. 1. The coated mass was determined via differential weighing of 20 randomized stents before and after the coating process.
To verify coating homogeneity 20 randomized stents and 3 expanded stents were studied by fluorescent microscopy (BZ-8000, Keyence Corporation, Japan, λ ex 360 nm, λ em 460 nm). The Stents were expanded in dry state via a balloon catheter and a catheter pump (6 atm, 15 s). Moreover 3 random stents were examined by scanning electron microscopy (Phenom, FEI Company, USA). The luminal and abluminal coating thickness of 2 random stents was determined on polished specimens via reflected-light microscopy (Confocal Laser Scanning Microscope LEXT OLS 3000, Olympus, Germany). To prepare the polished specimen a stent was embedded in EpoThin (Buehler, USA) and abraded via stepped wet grinding and polishing. The coating thickness was detected on the longitudinal section at 26 different points with two measuring lines.
To determine in vitro drug release 4 randomized stents were expanded and incubated in 10 mL of phosphate buffered saline pH 7.4 at 37 °C on a shaking device (300 rpm; Inkubator1000 and Titramax1000, Heidolph Instruments, Germany). To maintain sink conditions the release medium was completely replaced upon sampling. The triamterene content of the incubation buffer was determined fluorometrically (Varioskan Flash, Thermo Scientific, USA; λ ex 370nm, λ em 434nm).
Results
The average mass of uncoated goods was 29.16 ± 1.25 mg (n=20). After the coating process the average mass amounted to 31.15 ± 0.66 mg (n=20), resulting in a theoretical average drug content of approximately 480 µg/ stent. As shown in Fig. 1 and 2 the surface morphology is fairly uniform with rare coating defects at the terminal ends of the stents, most likely caused by mechanical impact during the coating process and the comparably stiff coating polymer. None of the inspected goods showed bridges between the struts. Singular coating defects were observed on expanded stents at the strut bends which seem to be the points of largest mechanical deformation during expansion. The mean abluminal coating thickness was 6.57 ± 2.14 µm, whereas the luminal coating thickness amounted to 1.02 ± 2.62 µm. The distribution of luminal and abluminal coating layer thickness is given in Fig. 3 and 4. It became apparent that the thickness of the abluminal stent surface was approximately 6 times higher and more homogeneous than the luminal surface. The highest irregularities in the luminal coating thickness were observed at the ends of the stents. The thin luminal coating and high deviations in distribution of luminal coating thickness is caused by the nature of the coating process and stent architecture. The release profile of 4 stents over 175 days is given in Fig. 5 . Within in the first 3 weeks elution was linear when plotted versus the square root of time (R 2 =0,998, Fig. 3 ), which is consistent with a sustained diffusion-controlled release mechanism. 
Discussion
Our findings indicate that the fluidized-bed process provides a powerful tool for large scale coating of stents. The percentage standard deviation between the mass of coated goods was well below 5 %. The coating process resulted in homogeneous coating surfaces with few irregularities at the ends of the stents. The tissue-facing abluminal stent surface featured a markedly higher coating thickness than the luminal surface, thus most of the drug containing layer is in direct contact with the site of action. Results of release testing show that drug release was diffusioncontrolled which can also be attributed to the presence of an intact coating layer. Taking the coating polymer and incorporated drug into account the process parameters have to be adapted to ensure a minimum of coating defects, especially at the terminal ends of the stents that are particularly exposed to mechanical impact during the coating process. Overall, these results provide a sound basis for mass production of drug-eluting stents via fluidized-bed technology.
